T1	Participants 105 120	newly diagnosed
T2	Participants 122 167	previously untreated chronic myeloid leukemia
T3	Participants 471 485	chronic phase.
T4	Participants 518 530	476 patients
T5	Participants 536 553	randomly assigned
